<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04637269</url>
  </required_header>
  <id_info>
    <org_study_id>BCMA CAR-T cell</org_study_id>
    <nct_id>NCT04637269</nct_id>
  </id_info>
  <brief_title>Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma</brief_title>
  <official_title>Anti-BCMA CAR-T Cell Therapy for the Relapsed or Refractory Multiple Myeloma: a Multi-center, Uncontrolled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Carbiogene Therapeutics Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xinqiao Hospital of Chongqing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with&#xD;
      relapsed and refractory B-cell hematologic malignancies. There are few effective treatments&#xD;
      for MM(multiple myeloma). BCMA (B cell maturation antigen) is a promising target for&#xD;
      malignant plasma cells. Therefore, we designed a clinical trial using anti-BCMA CAR-T cell&#xD;
      therapy for patients with relapsed and refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 17, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicity (DLTs)</measure>
    <time_frame>within 4 weeks after infusion</time_frame>
    <description>To characterize the safety, tolerability, and determine the recommended dosage of Anti-BCMA CAR-T Cells for the R/R Multiple Myeloma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of AEs and SAEs</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>To characterize the safety, tolerability, and determine the recommended dosage of Anti-BCMA CAR-T Cells for the R/R Multiple Myeloma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response</measure>
    <time_frame>up to 24 months after infusion</time_frame>
    <description>Response assessed by International Myeloma Working Group (IMWG) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>up to 24 months after infusion</time_frame>
    <description>Response assessed by International Myeloma Working Group (IMWG) criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>BCMA CAR-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the &quot;3 + 3&quot; dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-BCMA CAR-T</intervention_name>
    <description>5×10^7 /KG 15×10^7 /KG 45×10^7/KG Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days prior to cell infusion.</description>
    <arm_group_label>BCMA CAR-T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet the following criteria for inclusion in the study： 1) Male or female&#xD;
        subjects between the ages of 18 and 75（including critical values）； 2) Subjects&#xD;
        histologically confirmed as relapsed and refractory multiple myeloma.&#xD;
&#xD;
        Positive expression of BCMA(&gt;50%) in malignant plasma cells； Approved anti-tumor therapies,&#xD;
        such as systemic chemotherapy, systemic radiotherapy, and immunotherapy, have been&#xD;
        completed for at least 2 weeks before the precondition.&#xD;
&#xD;
        ECOG≤1； Life expectancy ≥ 3 months； Neutrophil absolute count ≥ 1×10^9/L； platelet count ≥&#xD;
        50×10^9/L； Absolute lymphocyte count ≥ 1×10^8/L ；&#xD;
&#xD;
        Adequate organ function reserve :&#xD;
&#xD;
        GPT, GST ≤ 2.5× UNL（upper normal limit）； Creatinine clearance (Cockcroft Gault&#xD;
        method）≥60mL/min； Serum total bilirubin ≤1.5× UNL； The left ventricular ejection fraction&#xD;
        (LVEF) ≥ 50% was diagnosed by echocardiography, and there was no clinically significant&#xD;
        pericardial effusion and ECG abnormality； Basic oxygen saturation in indoor natural air&#xD;
        environment &gt; 92%； It can establish the venous access needed for collection without the&#xD;
        contraindications of leukocyte collection； For female subjects of childbearing age, results&#xD;
        are negative in urine pregnancy test before screening and administration, and subjects&#xD;
        agree to take effective contraceptive measures at least one year after infusion; Male&#xD;
        subjects with partners' fertility must agree to use effective barrier contraceptive methods&#xD;
        at least one year after infusion, and avoid sperm donation； Voluntary signing of informed&#xD;
        consent;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Any of the following points shall be deemed as no entry into this study：&#xD;
&#xD;
        Other tumors except cured non-melanoma skin cancer, cervical cancer in situ, superficial&#xD;
        bladder cancer, breast duct cancer in situ, or other malignant tumors with complete&#xD;
        remission of more than 5 years)； Severe mental disorders； A history of genetic diseases&#xD;
        such as Fanconi anemia, Shudder-Dale syndrome, Costman syndrome, or any other known bone&#xD;
        marrow failure syndrome； Heart disease with grade III-IV heart failure [NYHA&#xD;
        classification], myocardial infarction, angioplasty or stenting, unstable angina or other&#xD;
        heart diseases with prominent clinical symptoms within one year before admission； Subjects&#xD;
        with any indwelling catheter or drainage tube (such as percutaneous nephrostomy tube, bile&#xD;
        drainage tube or pleura/peritoneum/pericardium catheter), should be excluded. (Special&#xD;
        central venous catheter is allowed)； Subjects with a history of CNS lymphoma, CSF malignant&#xD;
        cells, or brain metastasis； Subjects with a history of CNS disease,such as epilepsy,&#xD;
        cerebral ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease&#xD;
        involving CNS； Any of the following virological ELISA results are positive: HIV antibody,&#xD;
        HCV antibody, TPPA, HBsAg； Active infection requiring systematic treatment within 2 weeks&#xD;
        before single collection； Subjects with known severe allergic reactions to cyclophosphamide&#xD;
        or fludarabine, or diagnosed as the allergy； History of autoimmune diseases (e.g. Crohn&#xD;
        disease, rheumatoid arthritis, systemic lupus erythematosus) that cause end-organ damage or&#xD;
        require systemic immunosuppressive medications or systemic disease modifying drugs in the&#xD;
        past 2 years； Presence of pulmonary fibrosis； Subjects who have received other clinical&#xD;
        trial treatment within 4 weeks before participating in this trial should be excluded. Or&#xD;
        the signing date of informed consent is within 5 half-lives of the last application of&#xD;
        another clinical trial (whichever is longer)； Subjects with poor compliance due to&#xD;
        physiological, family, social, geographical and other factors, or those unable to cooperate&#xD;
        with the study plan or follow-up； At the discretion of the investigator, there are&#xD;
        complications requiring systemic corticosteroid therapy (≥ 5mg / day of prednisone or&#xD;
        equivalent dose of other corticosteroids) or other immunosuppressive drugs within 6 months&#xD;
        after this clinical research treatment； The lactating woman who is reluctant to stop&#xD;
        breastfeeding； Any other condition considered unsuitable by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xi Zhang</last_name>
    <role>Study Chair</role>
    <affiliation>Xinqiao Hospital of Chongqing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xi Zhang, MD phD</last_name>
    <phone>13808310064</phone>
    <phone_ext>+86</phone_ext>
    <email>zhangxxi@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruihao Huang</last_name>
    <phone>18984398751</phone>
    <phone_ext>+86</phone_ext>
    <email>1169731117@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Hematology, Xinqiao Hospital</name>
      <address>
        <city>ChongQing</city>
        <state>Chongqing</state>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xi Zhang, MD</last_name>
      <phone>+8613808310064</phone>
      <phone_ext>+8613808310064</phone_ext>
      <email>zhangxxi@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Ruihao Huang</last_name>
      <phone>+8618984398751</phone>
      <phone_ext>+8618984398751</phone_ext>
      <email>1169731117@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 14, 2020</last_update_submitted>
  <last_update_submitted_qc>November 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinqiao Hospital of Chongqing</investigator_affiliation>
    <investigator_full_name>Xi Zhang, MD</investigator_full_name>
    <investigator_title>Chef of Hematology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

